Liver Transplant CGM

Mount Sinai Health System

Status: Enrolling

Conditions: Type 2 Diabetes; Liver Transplant; Post Transplant Diabetes

Treatments: Device: Libre 3+

Study type: Observational

Funder types: Other

Identifiers

NCT07216508

STUDY-24-01098

Details and patient eligibility

About

This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.

Full description

Liver transplant participants will be recruited. Participants will wear a blinded sensor after hospital discharge for up to 30 days. Data can be shared with participant and the providers retrospectively. Participants will be invited to wear another blinded sensor at 6 and 12 months.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL

Exclusion criteria

• having a planned discharge to a rehabilitation or nursing facility,
• a contraindication to sensor placement,
• if discharge is anticipated to be >30 days post-transplant, or
• if recent transplant also included a kidney or pancreas transplant

Trial design

40 participants in 1 patient group

Participants post liver transplant

Description:

Participants who are discharged from after liver transplant.

Treatment:

Device: Libre 3+